Product Highlight - ZEMIDAPA

18 hours ago
Product Highlight - ZEMIDAPA
  • Convenient Fixed-Dose Combination: Small-sized, once-daily tablet for simplified treatment.1
  • Dual Add-On Power: GEMI/DAPA with MET delivers a 1.34% HbA1c reduction from baseline.2
  • Flexible Add-On Option: GEMI with MET/DAPA achieves a 0.86% HbA1c reduction.3

References:
1. MFDS. https://nedrug.mfds.go.kr/searchDrug.
2. Han KA, et al. Diabetes Obes Metab. 2024 Sep;26(9):3743-3752.
3. Lee BW, et al. Endocrinol Metab (Seoul). 2023 Jun;38(3):328-337.

For healthcare professionals only.


PHARMANIAGA MARKETING SDN BHD
Company No: 198401005734
No. 7 Lorong Keluli 1B, Kawasan Perindustrian Bukit, Raja Selatan, Seksyen 7,
Selangor Darul Ehsan 40000
Tel: (+60) 3342 9999 • Fax: (+60) 3341 7777

Related MIMS Drugs